Sutro Biopharma, Inc. (STRO): R&D Expense
$166.42M
Year ended 2025-12-31
$144.74M
Trailing 12 months to 2026-06-30
+6.7%
3-year compound annual growth
+16.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $166.42M | -34.0% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $252.04M | +39.7% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $180.43M | +31.5% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $137.17M | +31.4% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $104.40M | +35.7% | 2024-03-25, From 2021-01-01 |
| 2020-12-31 | $76.96M | +17.3% | 2023-03-30, From 2020-01-01 |
| 2019-12-31 | $65.61M | +20.9% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $54.26M | -0.7% | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | $54.64M | +25.5% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $43.55M | n/a | 2019-04-01, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $195.70M | +38.5% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $129.62M | +8.5% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $117.69M | -15.0% |
Compare STRO, IPSC, IBRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗